October 10, 2022 03:08 PM EDT
Deals
Pharma

At­trac­tive M&A op­tions? An­a­lysts break down what's hot right now

Zachary Brennan

Senior Editor

With the num­ber of bio­phar­ma ac­qui­si­tions in 2022 so far falling be­low re­cent years, the in­vest­ment bank SVB Se­cu­ri­ties on Sun­day pub­lished a new re­port …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times